Page 36 - ARNM-1-1

Advances in Radiotherapy
& Nuclear Medicine SIR-spheres Y-90 resin microspheres for HCC treatment

Table 1. Patient features at baseline and end of study Table 1. (Continued)
Patient feature Baseline End of study (n=22) Patient feature Baseline End of study (n=22)
(n=30) (n=30)
Age, years, mean (SD) 60.7 (8) Not reported Prior targeted therapy, n (%) Not applicable
BMI kg/m , mean (SD) 23.3 (2.7) Not reported No 28 (93.3)
2
Ethnicity: Vietnamese, 30 (100) Not applicable Yes (sorafenib) 1 (3.3)
n (%) Not reported 1 (3.3)
ECOG performance Prior interventional
status, n (%) treatments, n (%)
0 28 (93.3) 29 (100) a Surgery 17 (56.7%) Not applicable
1 2 (6.7) 0 (0) Lobectomy 1
Lost to follow-up Not applicable 1 Segmentectomy 2
BCLC stage , n (%) Wedge resection 1
b
No 0 (0.0) Not applicable Type not reported 13 d
A 8 (26.7) Percutaneous procedure 5 (16.7%)
B 14 (46.7) Radiofrequency ablation 4
C 8 (26.7) TACE liver cancer 1
D 0 (0.0) Liver transplantation, n 0 Not applicable
Missing 0 Note: Patients were assessed for ECOG performance status; however,
a
Child-Pugh class, n (%) only 22 patients had imaging available for tumor response assessments.
c
A 30 (100) 21 (95.5) b BCLC stage was determined at first diagnosis. P-value for comparison
between postbaseline to baseline (paired t-test and Wilcoxon
B 0 (0) 1 (4.5) signed-rank test) showed a nonstatistically significant difference.
Tumor location, n (%) Not applicable d Patients reported previous surgeries during the medical examination;
Right 27 (90) however, confirmation of data was not possible because electronic
health records were not in use during the study period.
Left 3 (10) Abbreviations: AFP: α-fetoprotein; ALP: Alkaline phosphatase;
Tumor burden, mean (SD) ALT: Alanine aminotransferase; AST: Aspartate aminotransferase;
BCLC: Barcelona Clinic Liver Cancer; BMI: Body mass index;
Diameter (cm) 8.6 (2.3) ECOG: Eastern Cooperative Oncology Group; GGT: γ-glutamyl
Volume (cm ) 318.7 (230.7) transferase; TACE: Transarterial chemoembolization.
3
Cirrhosis and hepatitis, Not applicable
n (%) mean volume (SD) was 318.7 (230.5) cm . Three patients
3
Cirrhosis 10 (33.3) had nontargeted tumors that were not treated with SIRT.
Chronic hepatitis
3.2. SIRT dosimetry and treatment
No 2 (6.7)
Hepatitis B 17 (56.7) Dosimetry was calculated using the BSA method for
Hepatitis C 1 (3.3) 14 patients and the partition model for 16 patients
Hepatitis D 10 (33.3) (Table 2). The mean prescribed activity was 1.9 GBq for
Laboratory values, Difference c the whole liver (n = 1), 1.2 GBq for the left lobe (n = 1), and
mean (SD) 1.3 GBq for the right lobe (n = 28). Most patients received
ALT (U/L) 43.7 (20.7) 44.2 (20.5) P>0.05 at least 90% of the prescribed activity; two did not. The
AST (U/L) 54.7 (30.8) 69.9 (76.2) P>0.05 mean normal liver dose (SD) delivered was 28.1 (9.9) Gy,
and the mean tumor dose (SD) delivered was 179.2 (80.3)
GGT (U/L) 145.8 (112.3) 176.4 (154.5) P>0.05 Gy. The mean lung shunt fraction (SD) was 5.4% (3.6), and
ALP (U/L) 150.3 (119.6) 91.2 (47.3) P>0.05 the mean lung dose (SD) was 3.5 (3.2) Gy.
Bilirubin (mg/dL) 13.2 (5.3) 17.6 (9.3) P>0.05
Albumin (mg/dL) 41.3 (3.6) 40.3 (5.9) P>0.05 3.3. Clinical effectiveness
AFP 2152 (5444) 509.1 (843.4) P>0.05 All patients were alive at 6 months. For all 30 patients,
Portal vein 0 (0.0) tumor responses at 3 months were 23.3% CR, 53.3% PR,
embolization, n (%) 20.0% SD, and 3.3% PD. For the 22 patients with tumor
(Cont’d...) response measurements at 6 months, 31.8% were CR,

Volume 1 Issue 1 (2023) 4 https://doi.org/10.36922/arnm.0385